NCT06976021View on ClinicalTrials.gov

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Triple Negative Breast CancerUterine Cervical CancerUterine Corpus CancerMalignant MelanomaClear Cell Renal Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

Baseline 89-Zr Pembrolizumab Immuno PET-CT

Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89

DIAGNOSTIC_TEST

Proteomic assay

Assessment of the proteomic profile before and periodically after treatment

DIAGNOSTIC_TEST

Follow-up 89-Zr Pembrolizumab Immuno PET-CT

Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89 after radiotherapy performed in patients who are not treated with immunotherapy

All Listed Sponsors
lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER